Reuters
29 Jun 2026, 05:20 UTC · 2h ago
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
29 Jun 2026, 05:20 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide passed a preliminary review for inclusion in China's basic medical insurance drug catalogue. — Inclusion in the national insurance catalogue dramatically increases patient access and sales volume for high-demand weight-loss/diabetes drugs in the Chinese market.
+0.60Which stocks this story touches
Its drug Ecnoglutide passed a preliminary review for inclusion in China's basic medical insurance catalogue.
Its mazdutide injection passed a preliminary review for inclusion in China's basic medical insurance catalogue.
Continue reading
6 related stories
Top 1 mover · tap to explore
[mutual] Both companies are seeking inclusion in China's medical insurance drug catalogue for their respective GLP-1 drugs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
